P

Plus Therapeutics

PSTV

1.80000
USD
0
(0.00%)
مغلق
حجم التداول
198
الربح لكل سهم
0
العائد الربحي
0
P/E
-0
حجم السوق
8,254,866

أصول ذات صلة

AMZN
-3.000
(-1.60%)
183.990 USD
DIS
-0.640
(-0.68%)
93.050 USD
NFLX
-3.53
(-0.56%)
624.46 USD
R
ROKU
-2.910
(-4.99%)
55.360 USD
T
TDOC
-0.85000
(-9.00%)
8.59000 USD
TTD
-2.100
(-2.34%)
87.780 USD
Z
ZM
-1.450
(-2.40%)
58.970 USD

الأخبار

المقالات

العنوان: Plus Therapeutics

القطاع: Healthcare
الصناعة: Biotechnology
Plus Therapeutics Inc is a clinical-stage pharmaceutical company that focuses on discovering, developing, and delivering complex treatments for patients with cancer and rare diseases. The company is working on a range of potential products, with its main programs targeting recurrent glioblastoma (GBM) and leptomeningeal metastases (LM). One of its key candidates, rhenium (186Re) obisbemeda, is specifically designed to treat central nervous system (CNS) cancers such as GBM, LM, and pediatric brain cancers (PBC).